Image Source: Pexels

Pfizer (PFE) is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales).

While Pfizer historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis.

Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Three key data points gauge Pfizer Inc or any dividend-paying firm.

The key three are:

(1) Price

(2) Dividends

(3) Returns

Those three basic keys best tell whether any company has made, is making, and will make money.

PFE Price

Over the past year, Pfizer's share price decreased about 39.25% from $48.39 to $29.39 as of Tuesday’s market close.

If Pfizer trades in the range of $26.00 to $36.00 this next year, its recent $29.39 share price might rise to $33.00  by next year. Of course, Pfizer’s price could drop about the same $3.61 estimated amount or more.

My annual upside estimate of $3.61 however, is in line with the median of price targets estimated by twenty-two analysts tracking PFE.

PFE Dividend

Pfizer Inc has paid Quarterly dividends since March 1986.  PFE’s most recent Q dividend of $0.42 was declared on December 14, 2023 to shareholders of record on January 25th. The payout is coming March 1.  You’ve got a couple of weeks to jump for the dividend.

The forward-looking $1.68 annual dividend yields 5.72% at Tuesday’s $29.39 share price.

PFE Returns

To put it all together, add the estimated annual dividend of $1.68 to the price upside of $3.61 to find a $5.29 gross gain.

At Monday’s $29.39 share price, a little over $1000 would buy 34 shares.

A $10 broker fee (if charged), paid half at purchase and half at sale, would cost us about $0.29 per share.

Subtracting that likely $0.29 brokerage cost from the $5.29 gross gain produces a net gain of $5.00 X 34 shares = $170.00 for a 17% estimated net gain.

You might choose to pounce on Pfizer It is a 175 year-old U.S. Pharmaceutical firm headquartered in New York, NY.

Furthermore, the estimated $57.20 of annual dividend income from $1k invested is about 1.45 times greater than PFE’s recent $29.39 single share price.

The exact track of Pfizer Inc ongoing future price and dividend will be determined by market action.

Remember the true value of any stock is best realized through personal ownership of shares.

More By This Author:

Current Analysis: Patterson
Current Analysis: Medical Facilities (MFCSF)
Current Analysis: Suncor Energy (SU)